Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
Makrakis D, Rounis K, Tsigkas AP, Georgiou A, Galanakis N, Tsakonas G, Ekman S, Papadaki C, Monastirioti A, Kontogianni M, Gioulbasanis I, Mavroudis D, Agelaki S. Makrakis D, et al. Among authors: agelaki s. PLoS One. 2023 Feb 10;18(2):e0277708. doi: 10.1371/journal.pone.0277708. eCollection 2023. PLoS One. 2023. PMID: 36763597 Free PMC article.
A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer.
Agelaki S, Veslemes M, Syrigos K, Palamidas F, Polyzos A, Papakotoulas P, Kentepozidis N, Milaki G, Tzanakis N, Kouroussis C, Vamvakas L, Georgoulias V; Hellenic Oncology Research Group. Agelaki S, et al. Lung Cancer. 2004 Mar;43(3):329-33. doi: 10.1016/j.lungcan.2003.08.031. Lung Cancer. 2004. PMID: 15165092 Clinical Trial.
A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer.
Agelaki S, Syrigos K, Christophylakis C, Boukovinas J, Varthalitis J, Pavlakou G, Athanasiadis A, Kouroussis C, Vardakis N, Maltezakis G, Milaki G, Georgoulias V; Lung Cancer Subgroup, Hellenic Oncology Research Group. Agelaki S, et al. Oncology. 2004;66(3):192-6. doi: 10.1159/000077994. Oncology. 2004. PMID: 15218309 Clinical Trial.
Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.
Apostolaki S, Perraki M, Kallergi G, Kafousi M, Papadopoulos S, Kotsakis A, Pallis A, Xenidis N, Kalmanti L, Kalbakis K, Agelaki S, Kalykaki A, Stournaras C, Stathopoulos E, Georgoulias V, Mavroudis D. Apostolaki S, et al. Among authors: agelaki s. Breast Cancer Res Treat. 2009 Oct;117(3):525-34. doi: 10.1007/s10549-008-0239-3. Epub 2008 Nov 19. Breast Cancer Res Treat. 2009. PMID: 19016323
A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer.
Bozionelou V, Kalbakis K, Vamvakas L, Agelaki S, Androulakis N, Kalykaki A, Georgoulias V, Mavroudis D. Bozionelou V, et al. Among authors: agelaki s. Cancer Chemother Pharmacol. 2009 Sep;64(4):785-91. doi: 10.1007/s00280-009-0928-6. Epub 2009 Jan 22. Cancer Chemother Pharmacol. 2009. PMID: 19159931 Clinical Trial.
165 results